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a  b  s  t  r  a  c  t
6:2  ﬂuorotelomer  alcohol  (6:2  FTOH)  was  evaluated  for  potential  systemic  repeated-dose
and  reproductive  toxicity  in  mice.  6:2  FTOH  was  administered  by oral  gavage  to  CD-1  mice
as a suspension  in 0.5%  aqueous  methylcellulose  with  0.1%  Tween-80  at dosages  of 1,  5,
25,  or 100  mg/kg/day.  The  no-observed-adverse-effect  level (NOAEL)  for  systemic  toxicity
was 25  mg/kg/day  (males)  and  5  mg/kg/day  (females),  based  on effects  at higher  doses  on
mortality,  clinical  observations,  body  weight,  nutritional  parameters,  hematology  (red  and
white  blood  cell),  clinical  chemistry  (liver-related),  liver  weights,  and  histopathology  (liver,
teeth, reproductive  tract,  and  mammary  gland).  However,  6:2  FTOH  was not  a selective
reproductive  toxicant.  The  NOAEL  for reproductive  toxicity  was  >100  mg/kg/day;  no  effects
on reproductive  outcome  were observed  at any  dosage.  The  NOAEL  for viability  and  growth
of the  offspring  was  25  mg/kg/day,  based  on  clinical  signs  of  delayed  maturation  in pups,
and reductions  in pup  survival  and pup  body  weight  during  lactation  at 100  mg/kg/day.
While  the  severity  of  the  effects  was  generally  greater  in  mice  than  previously  reported  in
CD rats,  the  overall  NOAELs  were  identical  in  both  species,  5  mg/kg/day  for systemic  toxicity
and  25 mg/kg/day  for offspring  viability/growth.  6:2 FTOH  was  not  a selective  reproductive
toxicant  in  either  species;  no  effects  on  reproductive  outcome  occurred  at any  dose  level,
and  any  effects  observed  in offspring  occurred  at dose  levels  that  induced  mortality  and
severe toxicity  in  maternal  animals.
©  2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is  an  open  access  article  under
the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Fluorotelomer alcohols [FTOHs; F(CF2CF2)nCH2CH2OH,
where n ≥ 3] are industrial raw materials used to manu-
facture ﬂuorotelomer-based products. The performance of
these products is largely derived from the ﬂuorotelomer
functionality, which is covalently bound as a side-chain
to a polymer backbone, or to additional hydrocarbon
∗ Corresponding author. Tel.: +1 302 366 5341; fax: +1 302 366 5211.
E-mail address: Pushkor.Mukerji@dupont.com (P. Mukerji).
http://dx.doi.org/10.1016/j.toxrep.2014.12.002
2214-7500/© 2014 The Authors. Published by Elsevier Ireland Ltd. Th
(http://creativecommons.org/licenses/by-nc-nd/3.0/).groups to create ﬂuorosurfactants [1–5]. Polymeric prod-
ucts provide oil and water repellency and stain release
protection that cannot be achieved with non-ﬂuorinated
alternatives. Fluorosurfactants provide unparalleled sur-
face tension lowering, wetting and leveling properties.
Recently, major global ﬂuorotelomer manufacturers have
committed to replace historic long-chain products that
are potential precursors to long-chain perﬂuorocarboxylic
acids (PFCAs, CnF2n+1COOH, where n ≥ 7), such as perﬂuo-
rooctanoate (PFOA) [6–8]. Alternatives, which cannot break
down to long-chain PFCAs, such as products based on
short-chain 6:2 FTOH (C6F13CH2CH2OH, CAS# 647-42-7,
is is an open access article under the CC BY-NC-ND license
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:2 FTOH) as a key raw material, have been approved by
egulators.
A substantial body of data describes 6:2 FTOH hazards,
nswering the call for more published information about
lternatives [9]. The developmental and reproductive tox-
city of 6:2 FTOH in CD rats as well as the acute, genetic, and
ubchronic toxicity in CD rats have been reported, includ-
ng a benchmark dose of 5 mg/kg/day [10,11]. There was
o portal of entry-speciﬁc toxicity observed for 6:2 FTOH
hen comparing repeated-dose oral and inhalation stud-
es [10,12]. In vitro 6:2 FTOH metabolism in mouse, rat and
uman hepatocyctes and in vivo oral and inhalation single
nd repeated-dose metabolism and kinetics studies have
een reported showing rapid metabolism and elimination
13–15]. Finally, the toxicity of two principal metabolism
nd environmental degradation products, perﬂuorohex-
noic acid, PFHxA [16–18] and 5:3 acid, C5F11CH2CH2COOH
19], have been reported.
The primary objective of this study was to evaluate the
ystemic oral repeated-dose and reproductive toxicity of
:2 FTOH in CD-1 mice. The CD-1 strain was chosen for
onsistency with previously published toxicological eval-
ations of ﬂuorotelomer alcohols and metabolites in mice
20–24]. The present evaluation of 6:2 FTOH in CD-1 mice
as intended to provide a basis for comparison with previ-
usly published repeated-dose and reproductive effects of
:2 FTOH in CD rats. Further, this evaluation encompasses
he toxicological action and effects of the parent chemi-
al and metabolites from its biotransformation, including
FHxA and 5:3 acid, resulting from 6:2 FTOH exposure in
ice.
. Materials and methods
.1. Test substance and administration
The test substance, 1-octanol, 3,3,4,4,5,5,6,6,7,7,8,8,8-
ridecaﬂuoro-, also known as 6:2 ﬂuorotelomer alcohol
6:2 FTOH; 99.7% purity; C6F13CH2CH2OH; CAS #647-42-
), was supplied by DuPont Chemicals and Fluoroproducts,
ilmington, Delaware, as a clear liquid. 6:2 FTOH was for-
ulated in a vehicle of 0.1% Tween-80 in 0.5% aqueous
ethylcellulose. Formulations were administered by intra-
astric intubation to achieve dosage levels of 0, 1, 5, 25,
nd 100 mg/kg body weight/day (mg/kg/day). Control ani-
als were administered the vehicle alone. All animals were
osed once each day at approximately the same time (±2 h)
t a dose volume of 5 mL/kg body weight (calculated from
he most recently collected body weight).
Analyses at ﬁve time points, including the beginning and
nd of the study, conﬁrmed that the formulations for the 5,
5, and 100 mg/kg/day groups were homogeneous mixed
t the targeted concentrations (±15% nominal) and stable
ntil use. The concentration and stability of the formulation
or the 1 mg/kg/day group could not be veriﬁed for the ﬁrst
ix weeks of the premating period for P1 males only, after
hich the formulation method was reﬁned, such that con-
entration, homogeneity, and stability were consistently
ithin the targeted range.orts 2 (2015) 130–143 131
2.2. Test species and animal husbandry
Male and female Crl:CD1(ICR) mice were acquired from
Charles River Laboratories, Inc. (Kingston, NY) and main-
tained in an AAALAC-accredited facility in accordance with
the principles described in the Guide to Care and Use of
Laboratory Animals [25]. Animals were housed individu-
ally in solid bottom caging with bedding and NestletsTM as
enrichment. Breeding pairs were housed together during
the cohabitation period and litters were housed with their
dams during the lactation period. Throughout the study,
animals were fed PMI® Nutrition International, LLC (St.
Louis, MO)  Certiﬁed Rodent LabDiet® 5002 and provided
with tap water ad libitum. Animal rooms were maintained
on a 12-h light/dark cycle (ﬂuorescent light), a temperature
of 22 ± 4 ◦C, and a relatively humidity of 50 ± 20%.
Males were approximately 39 days old at arrival and
50 days old at study start. Females (nulliparous and not
siblings of the males) were approximately 57 days old
upon arrival and 75 days old at study start. Mice were
released from quarantine for study use after an acclimation
period of approximately 1 week based on adequate body
weight gain and freedom from clinical signs of disease or
injury.
All mice were weighed approximately weekly and cage-
site examinations were performed at least twice daily to
detect moribund or dead animals. All mice were also exam-
ined approximately 1–3 h after dosing for clinical signs of
overt toxicity.
2.3. In-life and reproduction
The study was  performed in compliance with GLP stan-
dards and in accordance with the OECD, Section 4 (Part
415) and U.S. EPA, OPPTS 870.3550 guidelines. Animals
were divided by computerized, stratiﬁed randomization
into ﬁve groups of 15 males and 15 females such that
all animals were within 20% of the mean for the sex at
study start. Parental (P1) male mice were dosed for approx-
imately 70 days prior to mating, in order to encompass the
entire spermatogenic cycle; and throughout the cohabita-
tion period (≤2 weeks), up until the day before scheduled
euthanasia. P1 female mice were dosed for approximately
14 days prior to mating, and throughout the cohabitation
period (≤2 weeks), gestation, and lactation, up until the
day before scheduled euthanasia. F1 males and females that
were selected for developmental landmarks were dosed
from post-natal day (PND) 21 until the day before sched-
uled euthanasia.
Clinical observations, body weights, and food con-
sumption data were collected on all P1 generation mice
approximately weekly throughout the premating period.
During the cohabitation period, one male and one female
mouse within each dose group were housed continually
in the male’s cage until successful mating was veriﬁed
by an intravaginal copulation plug, at which time they
were returned to individual housing. The day copulation
was conﬁrmed was  designated as GD 0. For presumed
pregnant females, clinical observations, body weight, and
food consumption data were collected on GD 0, 4, 7, 11, 14,
and 17. The day a litter was delivered was  designated as
logy Rep132 P. Mukerji et al. / Toxico
lactation day (LD) 0. For dams that delivered a litter, clini-
cal observations and body weights were collected on LD 0,
7, 14, and 21, while food consumption data were collected
on LD 0, 7, and 14. The number of live and dead pups and
clinical observations for the pups were recorded once daily
during the postpartum period, and pup body weights were
collected on LD 0, 4, 7, 14, and 21. On LD 4, litters were
randomly reduced to eight pups each (four per sex when
possible).
For the 1, 5, and 25 mg/kg/day groups, offspring in
the F1 litters of each treatment level were randomly
selected (one animal/sex/litter when possible) to be eval-
uated for collection of developmental landmark data.
For the 100 mg/kg/day group, all offspring were eutha-
nized as weanlings (PND 21) due to concerns about their
ability to survive without the dam, based on low pup
body weights and high pup mortality. Clinical observa-
tions, body weights, and food consumption data were
collected on all surviving F1 generation mice weekly from
PND 21 until PND 40–43. The age and body weight
at either vaginal opening or preputial separation were
recorded.
2.4. Anatomic pathology
All P1 mice and F1 adults were euthanized by isoﬂurane
anesthesia followed by exsanguination, after completion
of the cohabitation period for P1 males (on test days
107–109), on postpartum day 21 for P1 females, on test
day 59 for P1 females that did not deliver a litter, and after
developmental landmark achievement for all F1 adults (on
PND 40–43). F1 weanlings designated for gross evaluations
were euthanized by isoﬂurane anesthesia followed by CO2
inhalation. The order of euthanasia was stratiﬁed across
groups.
All P1 mice, F1 weanlings, and F1 adults underwent an
examination of the external surface, all oriﬁces, and the
cranial, thoracic, abdominal, and pelvic cavities, including
viscera. The following tissues from P1 mice were weighed
and retained in an appropriate ﬁxative: brain, liver (with
gallbladder), and kidneys from males and females; testes
and epididymides from males; and ovaries (with oviducts)
and uterus (with cervix) from females. Relative organ
weights (% of terminal body weight) were calculated. In
addition, the following tissues from P1 mice were retained
in a ﬁxative: nose (I & II) with teeth, pancreas; seminal
vesicles, coagulating gland, and prostate from males; and
vagina and mammary gland from females. F1 pups that
either died or were euthanized prior to the scheduled
necropsy were examined grossly.
Microscopic examination of hematoxylin and eosin
(H&E) stained parafﬁn sections were performed by a vet-
erinary pathologist on all tissues collected from P1 animals
from the control and high-dose groups, from all P1 pairs
that failed to produce a litter, and from all parental animals
dying spontaneously (i.e., found dead) or euthanized prior
to scheduled necropsy. In addition, the following organs
from all P1 adult mice from all dose levels were processed
to slides and examined microscopically: liver, nose/teeth,
ovaries, uterus, vagina, and mammary gland.orts 2 (2015) 130–143
2.5. Clinical pathology
Each group of P1 males and females was divided into
two  approximately equally sized subsets for hemato-
logy or clinical chemistry. Blood samples for hematology
(5–8 animals/sex/group) or clinical chemistry (6–8 ani-
mals/sex/group) measurements were collected from the
vena cava while each animal was under isoﬂurane anes-
thesia.
The following parameters were assessed with a Bayer®
Advia 120 hematology analyzer: red blood cell count
(RBC), hemoglobin (HGB), hematocrit (HCT), mean cor-
puscular (cell) volume (MCV), mean corpuscular (cell)
hemoglobin, mean corpuscular (cell) hemoglobin concen-
tration (MCH), red cell distribution width (RDW), absolute
reticulocyte count (ARET), platelet count, white blood cell
count, and differential white blood cell count. The following
parameters were assessed with an Olympus® AU640 clin-
ical chemistry analyzer: aspartate aminotransferase (AST),
alanine aminotransferase (ALT), sorbitol dehydrogenase
(SDH), alkaline phosphatase (ALKP), total bilirubin (BILI),
urea nitrogen (BUN), creatinine (CREA), cholesterol (CHOL),
triglycerides, glucose, total protein, albumin, globulin, cal-
cium, inorganic phosphorus, sodium, potassium, chloride,
and total bile acids (TBA).
2.6. Statistical analyses
Litter survival and indices for mating, fertility, and ges-
tation were compared using Fisher’s Exact test [26] with
a Bonferroni–Holm correction [27]. For all other continu-
ous numerical data, transformations were applied when
appropriate, based on preliminary tests for homogeneity of
variance [28] and normality [29]; and a one-way analysis
of variance [30] followed by Dunnett’s test [31] were con-
ducted. For all statistical analyses, signiﬁcance was  judged
at p < 0.05.
3. Results
3.1. Mortality and clinical observations in P1 mice
6:2 FTOH-related clinical abnormalities and mortality
were observed in P1 males and females at 100 mg/kg/day
(data not shown). One male and two females at this
dose level were found dead or humanely euthanized dur-
ing the premating or gestation periods. Clinical signs of
toxicity that preceded death in these animals included
clonic and tonic convulsions, ataxia, tremors (head/upper
body/forelimbs), hyperreactivity, increased muscle tone,
lethargy, pallor, labored breathing, and gasping. Simi-
lar signs of toxicity were also observed in 3 additional
mice (1 male and 2 females) in the 100 mg/kg/day dose
group that survived to the scheduled euthanasia. When
the clinical abnormalities did not result in death, they
abated within approximately one week after the ﬁrst
occurrence. There were no 6:2 FTOH-related clinical obser-
vations or mortality in P1 males or females at dose levels
≤25 mg/kg/day.
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Table  1
P1 in-life parameters.
Dose (mg/kg/day) 0 1 5 25 100
Males 14 15 15 15 14
Final  body weight (day 105) 42.4 (2.9) 42.9 (3.2) 42.2 (2.9) 40.4 (2.2) 40.4 (3.2)
Body weight gain (days 0–105) 11.6 (2.3) 12.1 (3.7) 11.6 (2.2) 11.0 (1.7) 10.2 (2.9)
Daily food consumption (days 0–70) 5.8 (0.6) 5.9 (0.5) 5.8 (0.5) 5.6 (0.5) 5.4 (0.5)
Females – premating 15 15 15 15 14
Body  weight (day 14) 27.3 (1.3) 27.7 (1.4) 27.7 (1.5) 27.9 (1.8) 27.4 (1.1)
Body weight gain (days 0–14) −0.1 (0.9) 0.4 (0.9) 0.3 (1.7) 0.3 (1.2) −0.1 (1.1)
Daily food consumption (days 0–14) 4.6 (0.5) 4.6 (0.5) 4.9 (0.5) 4.6 (0.5) 5.0 (0.5)
Females – gestation 14 14 14 14 10
Body  weight (GD 17) 52.1 (4.0) 54.7 (5.5) 54.0 (4.1) 54.5 (4.6) 53.4 (3.9)
Body weight gain (GD 0–17) 25.2 (3.1) 27.6 (4.4) 26.9 (3.6) 26.7 (3.5) 24.4 (4.9)
Daily food consumption (GD 0–17) 6.4 (0.7) 6.3 (0.6) 6.5 (0.5) 6.3 (0.7) 6.3 (0.4)
Females – lactation 13 14 15 14 9
Body  weight (LD 21) 39.2 (2.8) 41.5 (4.4) 39.9 (3.7) 40.4 (3.4) 35.7 (2.9)
Body weight gain (LD 0–21) 3.8 (3.2) 6.0 (3.1) 4.9 (2.8) 5.1 (3.3) 1.7 (2.9)
Daily food consumption (LD 0–14) 17.6 (2.3) 17.7 (1.5) 17.6 (1.6) 17.3 (1.4) 10.5 (1.7)#
Numbers of animals completing each phase are listed. Data are presented as mean (standard deviation). Units are grams (body weight parameters) and
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.2. Body weight and nutritional parameters in P1 mice
Among P1 males administered 100 mg/kg/day,
ean values for ﬁnal body weight (test day 105),
ody weight gain (test days 0–105), food consump-
ion (test days 0–70), and food efﬁciency (test days
–70) were 4.8%, 11.6%, 7.5%, and 12.6% lower than
ontrol means (not statistically signiﬁcant), respectively,
nd were attributed to 6:2 FTOH (Table 1). There were
o effects on body weight or nutritional parameters in P1
ales at dose levels ≤25 mg/kg/day.
For P1 females during premating and gestation, there
ere no effects on body weight or nutritional param-
ters at any dose level (Table 1). During the lactation
eriod, P1 females administered 100 mg/kg/day exhibited
tatistically signiﬁcantly lower body weight gain, food con-
umption, and food efﬁciency during the intervals LD 0–7
nd LD 7–14, compared with controls, resulting in statis-
ically signiﬁcantly lower body weight on LD 7 and LD
4 (Table 1, Fig. 1). Compared with controls, mean body
eights were 20% lower on LD 14 and mean food consump-
ion was 51% lower from LD 7 to 14. There were no effects
n body weight or nutritional parameters in P1 females at
ose levels ≤25 mg/kg/day.
.3. Reproductive performance of P1 mice
There were no effects in reproductive performance
mating index, gestation index, fertility index, precoital
nterval, gestation length, number of implantation sites, or
ost implantation loss) at any dose level (Table 2).
.4. In-life data for F1 offspring
Litters of dams administered 100 mg/kg/day exhibited
:2 FTOH-related reductions in pup survival and body
eight (Fig. 2), and clinical abnormalities associated with
elayed maturation (data not shown). At 100 mg/kg/day,
up survival was statistically signiﬁcantly lower thancontrol on LD 14 and 21, and over the interval LD 4–21
(45% reduction in lactation index; Table 2). Mean pup body
weights were statistically signiﬁcantly lower than control
on LD 4, 7, 14, and 21, achieving a decrement of 65% lower
than control on LD 21. Pups in four litters at this dose level
were observed with closed eyes on lactation day 21, due
to delayed maturation. All F1 pups at the 100 mg/kg/day
dose level were euthanized on LD 21 due to concerns about
their ability to survive without the dam. There were no
differences in pup viability, survival, clinical observations,
or body weight at any other dose level. No differences in
live born or viability indices, litter size, or sex ratio were
observed at any dose level.
Among F1 males and females selected for further eval-
uation after weaning, there were no effects or statistically
signiﬁcant differences in the age at attainment of preputial
separation or vaginal patency, body weight parameters,
and nutritional parameters; and no clinical abnormalities
or mortality, at dose levels ≤25 mg/kg/day, which was the
highest level evaluated due to the early termination of the
100 mg/kg/day group (Table 3).
3.5. Hematology in P1 mice
6:2 FTOH exposure at 100 mg/kg/day resulted in hema-
tology ﬁndings for both red and white cell parameters
in males and females (Fig. 3). Group mean red cell mass
parameters (RBC, HGB, and HCT) were minimally to mildly
decreased by up to 11 and 17%, in males and females,
respectively (statistically signiﬁcant for most parameters).
In females, but not males, red cell mass changes were
associated with an increase in ARET (132% above con-
trols). Additional parameters reﬂecting these changes in
red blood cell mass included minimal (less than 10%
change compared to controls) but statistically signiﬁcant
decreased MCV  in males (4% below control), increased
RDW in males (8% above control), and decreased MCH  in
females (6% below control). Total white blood cells were
increased by 41% (males) and 110% (females), and were
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Fig. 1. P1 in-life parameters during lactation. Mean values are displayed. #Signiﬁcantly different (p < 0.05) from control by Dunnett’s test.
Table 2
Reproductive parameters and F1 litter data.
Dose (mg/kg/day) 0 1 5 25 100
Number of females paired 15 15 15 15 14
Number of females mated 14 15 14 15 11
Number of pregnant females 14 14 14 14 11
Number of females that littered 15 14 15 14 12
Mating index (%)a 100 100 100 100 100
Fertility index (%)b 100 93.3 100 93.3 100
Gestation index (%)c 100 100 100 100 100
Viability index (%)d 93.7 100 99.5 100 90.3
Lactation index (%)e 99.0 100 100 99.1 54.5#
Precoital interval (days) 2.0(1.2)f 2.0(1.1) 2.2(1.3) 2.6(1.8) 2.5(1.6)
Mean  gestation length (days) 18.9(0.3) 18.8(0.4) 19.0(0.1) 19.0(0.3) 18.9(0.5)
Implantations 11.7(1.5) 12.1(1.6) 11.5(2.5) 12.1(1.9) 11.2(3.3)
Number of pups born 11.0(2.0) 11.5(1.5) 11.3(2.7) 11.1(1.7) 11.6(1.6)
Number of pups born alive 11.0(2.0) 11.5(1.5) 11.3(2.7) 11.0(1.8) 11.4(1.3)
Sex  ratio (% males) 52.0(20.6) 51.6(8.5) 47.6(15.9) 40.7(14.6) 48.8(19.9)
a Number copulated/number paired.
b Number pregnant/number copulated.
c Number of litters with at least 1 live pup/number of litters.
d Number of pups alive on day 4/number of pups born alive.
4 post-ce Number of live pups on lactation day 21/number of live pups on day 
f Data are presented as mean (standard deviation).
# Signiﬁcantly different (p < 0.05) from control by Dunnett’s test.
associated with statistically signiﬁcant increases in females
(but not males) in absolute neutrophil, lymphocyte, and
monocyte counts (data not shown).
No effects or statistically signiﬁcant differences in
hematology parameters were observed in males or females
at dose levels ≤25 mg/kg/day.
Table 3
F1 in-life parameters.
Dose (mg/kg/day) 0 
F1 males 13 
Body  weight gain (PND 21–40) 18.0(2.1) 
Daily  food consumption (PND 21–40) 5.4(0.6) 
Age  at preputial separation achievement 28.3(1.5) 
F1  females 13 
Body  weight gain (PND 21–40) 11.2(1.2) 
Daily  food consumption (PND 21–40) 4.8(0.4) 
Age  at vaginal patency achievement 29.8(2.2) 
Numbers of animals completing each phase are listed. Data are presented as me
(food  consumption), and post-natal days (preputial separation or vaginal patency aulling.
3.6. Clinical chemistry in P1 miceEffects on liver-associated clinical chemistry parame-
ters were observed in males and females administered
100 mg/kg/day (Fig. 4). Changes for AST, ALT, ALKP, SDH,
and TBA were generally mild to moderate in males and
1 5 25
14 15 14
18.0(2.3) 17.5(1.5) 18.2(1.7)
5.7(0.5) 5.4(0.4) 5.4(0.5)
27.5(1.2) 27.3(1.7) 27.9(1.5)
14 14 14
11.0(1.4) 11.8(1.2) 11.2(1.9)
4.9(0.4) 5.1(0.4) 4.9(0.5)
29.4(2.6) 29.2(2.8) 30.2(2.2)
an (standard deviation). Units are grams (body weight gain), grams/day
chievement). There were no statistically signiﬁcant differences (p < 0.05).
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oderate to severe in females, as group mean liver parame-
ers were increased approximately 2.5- to 5-fold compared
o controls in males, whereas in females, most parameters
ere increased by greater than 5-fold and by as much as
9-fold (TBA in females) compared to controls. Although
ot statistically signiﬁcant, minimal increases in total BILI
n these groups may  also have been 6:2 FTOH-related. Ele-
ations in some liver parameters (AST, ALT, SDH, and TBA,
ut not ALKP or BILI) in one 25 mg/kg/day female were
ssociated with microscopic lesions in the liver and were
ttributed to 6:2 FTOH exposure.
Effects on other clinical pathology parameters in males
nd females at 100 mg/kg/day included decreases in the
ollowing (data not shown): BUN, decreased by 28% and
8% in males and females, respectively; CREA, decreased by
7 and 20%, respectively; and CHOL (males only; decreased
y 35%). In addition, potassium was minimally higher in
ales and females at 100 mg/kg/day (23 and 15% above
he controls, respectively; statistically signiﬁcant in males
nly)
There were no effects on clinical chemistry parameters
n males at dose levels ≤25 mg/kg/day, or in females at dose
evels ≤5 mg/kg/day.yed. #Signiﬁcantly different (p < 0.05) from control by Dunnett’s test.
3.7. Organ weights in P1 mice
Primary organ weight effects were observed in the liver
of males and females at 100 mg/kg/day, and in the kidneys
of males at 100 mg/kg/day (Tables 4 and 5). In addition,
reproductive organ weight changes occurring secondary to
body weight decrements were observed in male and female
reproductive organs (Tables 4 and 5).
Group mean liver weight parameters were increased
in both sexes (only liver weight relative to body weight
was statistically signiﬁcant), although these increases were
greater in females compared to males (liver weight relative
to body weight was  increased 13% and 24% above control,
in males and females, respectively).
Group mean kidney weight parameters were increased
in males at 100 mg/kg/day (up to 25% above controls; sta-
tistically signiﬁcant). These increases were not associated
with relevant changes in kidney-related clinical pathology
parameters or with microscopic changes in the kidney. Kid-
ney weight relative to body weight was minimally higher
in females at 100 mg/kg/day (11% above control; statis-
tically signiﬁcant). However, there were no statistically
signiﬁcant changes in other kidney weight parameters, and
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Fig. 3. P1 hematology parameters. Groups 1, 2, 3, 4, and 5 correspond to doses of 0, 1, 5, 25, and 100 mg/kg/day, respectively. Mean values and standard
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Table  4
P1 organ weights (males).
Dose (mg/kg/day) 0 1 5 25 100
No.  examined (14) (15) (15) (15) (14)
Absolute
Terminal body weight 41.9(3.1) 54.8(2.9) 42.0(2.6) 40.6(2.2) 39.4(2.9)
Liver  2.162(0.235) 2.140(0.219) 2.054(0.202) 2.093(0.162) 2.296(0.264)
Kidneys 0.659(0.117) 0.692(0.101) 0.6613(0.054) 0.710(0.089) 0.773(0.123)#
Epididymides 0.123(0.014) 0.125(0.014) 0.125(0.001) 0.121(0.011) 0.123(0.016)
Testes  0.235(0.027) 0.253(0.031) 0.258(0.040) 0.230(0.021) 0.254(0.028)
Relative
Liver  5.159(0.402) 5.000(0.417) 4.903(0.483) 5.163(0.353) 5.817(0.368)#
Kidneys 4.564(0.207) 1.613(0.175) 1.576(0.191) 1.748(0.190) 1.959(0.260)#
Epididymides 0.296(0.046) 0.294(0.038) 0.299(0.031) 0.298(0.033) 0.313(0.048)
Testes  0.565(0.076) 0.593(0.085) 0.616(0.094) 0.568(0.066) 0.647(0.086)#
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Data are presented as mean (standard deviation). Absolute weights are re
# Signiﬁcantly different (p < 0.05) from control by Dunnett’s test.
o treatment-related changes in kidney-related clinical
athology parameters or kidney histopathology. Therefore,
his change in female mice was considered to be unrelated
o 6:2 FTOH administration.
Organ weight changes occurring secondary to body
eight decrements were observed in male and female
eproductive organs. Absolute and relative ovarian and
terine weight parameters were moderately to markedly
ecreased in females at 100 mg/kg/day. Ovarian weights
ere decreased by up to 24% compared to controls,
nd uterine weights were decreased by up to 56% com-
ared to controls (statistically signiﬁcant for most weight
arameters). Testes weight relative to body weight was
tatistically increased (15% above control) in males at
00 mg/kg/day.
There were no effects or statistically signiﬁcant differ-
nces in organ weight parameters in males or females at
ose levels ≤25 mg/kg/day.
.8. Histopathology in P1 mice
.8.1. Liver
Microscopic ﬁndings indicative of trophic and toxic
ffects on the liver were present in males and females
t 100 mg/kg/day and in low incidences in females at
5 mg/kg/day (Table 6). These changes were generally
able 5
1 organ weights (females).
Dose (mg/kg/day) 0 1 
No.  examined (13) (15) 
Absolute
Terminal body weight 39.2(2.8) 40.6(5.7) 
Liver  2.809(0.329) 3.070(0.605) 
Kidneys 0.514(0.027) 0.525(0.090) 
Ovaries 0.0316(0.0045) 0.0370(0.0088) 
Uterus 0.264(0.131) 0.202(0.068) 
Relative
Liver 7.162(0.604) 7.512(0.774) 
Kidneys 1.316(0.086) 1.293(0.113) 
Ovaries 0.081(0.012) 0.093(0.025) 
Uterus 0.675(0.334) 0.515(0.211) 
ata are presented as mean (standard deviation). Absolute weights are reported 
# Signiﬁcantly different (p < 0.05) from control by Dunnett’s test.in grams; relative weights are reported as percent terminal body weight.
more severe in females and included hepatocellular
hypertrophy, oval cell hyperplasia, single cell necrosis
of hepatocytes, and cystic degeneration (females only).
Minimal microscopic hepatocellular hypertrophy was also
present in males at 5 and 25 mg/kg/day and in females at
5 mg/kg/day.
Hepatocellular hypertrophy was  most prominent in
centrilobular regions and was characterized by enlarged
hepatocytes containing increased amounts of pale to
brightly eosinophilic granular cytoplasm and enlarged
nuclei which often had prominent and multiple nucleoli.
Hyperplastic oval cells, small spindiloid cells containing
fusiform to oval nuclei and scant basophilic cytoplasm,
radiated from periportal regions into the surrounding
parenchyma and were often admixed with inﬂammatory
cell inﬁltrates. Single cell necrosis (or apoptosis) of hepato-
cytes was most conspicuous in periportal regions and was
characterized by individual shrunken, hypereosinophilic
cells containing pyknotic nuclei. Focal to multi-focal areas
of cystic degeneration, likely resulting from dropout of
degenerate hepatocytes, were characterized by variably-
sized cystic areas containing ﬂocculent to homogenous
eosinophilic material, often admixed with inﬂammatory
cell inﬁltrates.
No microscopic effects were observed in the liver of
males or females at 1 mg/kg/day.
5 25 100
(15) (15) (10)
39.9(3.7) 39.8(4.2) 35.4(2.9)
3.005(0.418) 3.048(0.526) 3.162(0.640)
0.516(0.038) 0.546(0.059) 0.515(0.051)
0.0342(0.0055) 0.0355(0.0095) 0.0244(0.0032)#
0.198(0.058) 0.203(0.068) 0.118(0.069)#
7.510(0.537) 7.624(0.911) 8.873(1.341)#
1.296(0.081) 1.376(0.114) 1.454(0.080)#
0.086(0.017) 0.089(0.023) 0.069(0.010)
0.505(0.178) 0.518(0.198) 0.332(0.176)#
in grams; relative weights are reported as percent terminal body weight.
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Table 6
P1 histopathology of liver.
Dose (mg/kg/day): no. examined Male Female
0(15) 1(15) 5(15) 25(15) 100(15) 0(15) 1(15) 5(15) 25(15) 100(15)
Hypertrophy, hepatocellular 0 0 9 10 15 0 0 13 12 13
Mitotic  ﬁgures, increased 0 0 0 0 5 0 1 0 1 10
Oval  cell hyperplasia 0 0 0 0 15 0 0 0 2 12
Cystic  degeneration 0 0 0 0 0 0 0 1 1 7
Single  cell necrosis 0 0 0 
Inﬁltrate, mononuclear (oval cell associated) 0 0 0 
Pigment, increased 0 0 0 
3.8.2. Teeth
6:2 FTOH-related changes in the incisor teeth, con-
sistent with ﬂuoride exposure, were present in males
and females at 100 mg/kg/day. These changes included
degeneration and atrophy of ameloblastic epithelium,
accentuation of the normal laminar pattern of dentin
and an increase in observed incomplete decalciﬁcation
of enamel and/or dentin. Degeneration and atrophy of
ameloblasts was characterized by segmental disorgani-
zation and attenuation of ameloblastic epithelium of the
incisor teeth. Lamination of dentin was characterized
by the presence of concentric basophilic rings within
the dentin of these teeth. Incomplete decalciﬁcation of
enamel and dentin was characterized by an increase in the
observed presence of basophilic, mineralized debris in the
enamel space of the incisor between the dentin and the
gingiva. Normally, this material is lost during processing
of slides and is not visible, but it is observed sporadically
in control mice due to vagaries in processing. How-
ever, this ﬁnding was observed at a higher incidence and
extent in males and females administered 100 mg/kg/day.
Incomplete decalciﬁcation of nasal bones, also consistent
with ﬂuoride exposure, was observed in some animals
at the 100 mg/kg/day dose level. There were no adverse
changes in the teeth of males or females at dose levels
≤25 mg/kg/day.
3.8.3. Female reproductive tract and mammary gland
Eight of 11 nursing dams in the 100 mg/kg/day group
that survived to the scheduled euthanasia at weaning were
in anestrus. No dams in the control or other treated groups
were anestral. Anestrus was characterized by marked thin-
ning of the vaginal mucosal epithelium (which was  often
only a single cell layer thick), uterine involution and atro-
phy of ovarian interstitial cells. In the mammary glands
of nursing dams in the 100 mg/kg/day group that sur-
vived to weaning, microscopic changes included decreased
milk secretion (in 8/11 dams), characterized by lactational
hypertrophy and hyperplasia of glandular epithelium con-
sistent with an actively nursing dam, but with few or
no alveoli containing proteinaceous secretion, and appar-
ent mineralization (deep basophilic staining) of glandular
secretion (in 11/11 dams).
No treatment-related changes in reproductive tract his-
tology, estrus cyclicity or mammary glands were observed
at dose levels ≤25 mg/kg/day, where body weight and
nutritional parameters in both dams and offspring were
similar to controls.0 12 2 1 1 1 12
0 15 0 0 0 0 10
0 15 0 0 0 0 0
3.9. Gross pathology in F1 mice
There were no 6:2 FTOH-related gross ﬁndings in F1
pups or weanlings at dose levels ≤100 mg/kg/day, nor in F1
adults at dose levels ≤25 mg/kg/day (the highest level eval-
uated due to the early termination of the 100 mg/kg/day
group).
4. Discussion
The primary objective of this study was to evaluate the
oral systemic repeated-dose and reproductive toxicity of
6:2 FTOH in CD-1 mice. Results from the present eval-
uation in mice, in conjuction with previously published
results using CD rats [10,11], provide a basis for compari-
son between commonly used outbred strains of two rodent
species.
4.1. Repeated-dose systemic and reproductive toxicity of
6:2 FTOH in mice
At 100 mg/kg/day, mortality was observed in 1/15 male
and 2/15 female mice, as well as clinical signs of behav-
ioral and physiological dysfunction, and reductions in body
weight and nutritional parameters. Reductions in body
weight were 5% in P1 males and 20% in P1 females. Alter-
ations in red blood cell parameters at this dose level may
be secondary to the body weight reductions [32]. In gen-
eral, the alterations in red blood cell parameters were
more severe in females than in males, and were associ-
ated with a regenerative response only in females, which
corresponded to the sex difference in body weight reduc-
tions. Increased white blood cell counts at 100 mg/kg/day
in males and females likely represent an inﬂammatory
response to liver toxicity. Elevated clinical chemistry
parameters indicative of hepatocellular injury (AST, ALT,
ALP, SDH, and TBA) were greater in females than males at
100 mg/kg/day, and were also observed in one female (and
no males) at 25 mg/kg/day.
Correspondingly, histopathologic alterations in the liver
were more severe in females than males. While liver
weights were increased in both sexes at 100 mg/kg/day,
adverse microscopic liver effects (including singe cell
necrosis, cystic degeneration, oval cell hyperplasia and
increased pigment) were observed in females at dose
levels ≥25 mg/kg/day and males at 100 mg/kg/day. In addi-
tion, decreases in BUN, CREA, and/or CHOL were observed
in males and females at 100 mg/kg/day; the decreases
may  be secondary to the liver toxicity observed at this
logy Reports 2 (2015) 130–143 139
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Table 7
NOAELs of 6:2 FTOH in rats and mice.
Mice Ratsa
Overall
Systemic toxicity 5 5
Reproductive toxicity >100b >250b
Pup viability/growth 25 25
Individual parameters
Mortality 25 25
Adverse clinical observations 25 25
Liver histopathology 5 5
Tooth histopathology 25 125
Hematology (red blood cell) 25 5
Hematology (white blood cell) 25 >250b
Clinical chemistry 5 5
Maternal body weight (lactation) 25 125
Pup survival 25 25P. Mukerji et al. / Toxico
ose level [33] but may  also be in response to food con-
umption reduction and/or to hepatic enzyme induction
34]. Hepatocellular hypertrophy was observed at dose
evels ≥5 mg/kg/day in both sexes, but was considered
on-adverse when it occurred in the absence of correlative
iver weight changes or histologic evidence of hepatotoxi-
ity, based on industry standards and regulatory guidance
8,35].
The ﬁndings of hepatocellular hypertrophy were mor-
hologically consistent with peroxisome proliferation and,
long with increased mitotic ﬁgures, were consistent
ith the known trophic effects produced in the liver
f rodents by peroxisome proliferator-activated recep-
or (PPAR) alpha agonists [36]. Microscopic evidence of
epatotoxicity included single cell necrosis and cystic
egeneration. Hyperplastic oval cells likely represent a
egenerative response to liver cell injury and are consid-
red to arise from terminal ductule epithelial cells (canal
f Hering cells) within periportal regions of the liver [37].
6:2 FTOH has been shown to rapidly metabolize
ith formation of ﬂuoride [13,38]. Microscopic alter-
tions of incisor teeth in both male and female mice
t 100 mg/kg/day included degeneration and atrophy of
meloblastic epithelium (an adverse change), lamination
f dentin, and incomplete decalciﬁcation of enamel and/or
entin. Changes in the ameloblastic epithelium and lam-
nation of dentin have been previously described in the
at incisor following ﬂuoride exposure [39–41]. Incomplete
ecalciﬁcation of teeth and bone are likely the result of
uoride-associated resistance to the acid decalciﬁcation
rocedure used in this study, as ﬂuoride can reduce the acid
olubility of mineral in teeth and bones [42,43] and as such,
his ﬁnding was considered to be indicative of exposure to
 metabolized ﬂuoride, but non-adverse.
Reproductive organ weight parameters and/or histol-
gy were altered in males and females as secondary effects
f decrements in body weight and nutritional parameters
t 100 mg/kg/day. In males, an increased ratio of testes
eight to body weight was attributed to body weight
oss, as testes weights are known to be stable with mod-
rate levels of body weight loss [44] and there were no
orrelative histologic ﬁndings in the testes. In females at
his dose level, ovarian and uterine weight parameters
ere decreased, which corresponded to microscopic ﬁnd-
ngs including anestrus with associated atrophic changes
n the reproductive tract, and secretory depletion in the
ammary gland. Anestrus and the correlative microscopic
hanges in the female reproductive tract are common non-
peciﬁc ﬁndings associated with reduced food intake and
tress [45]. Secretory depletion in the mammary gland is
ikely the result of increased duration of nursing in the
ndernourished pups at 100 mg/kg/day, as undernourished
at pups from diet-restricted dams have increased duration
f suckling compared to controls, especially toward the end
f lactation [46].
The following changes were attributed to 6:2 FTOH
xposure but non-adverse based on lack of association
ith organ injury or evidence of decreased func-
ion, as described above: increased kidney weights
100 mg/kg/day males), incomplete decalciﬁcation of
namel and dentin (25 mg/kg/day females), and minimalPup body weights 25 25
a [10,11].
b Highest dose evaluated in the study.
hepatocellular hypertrophy (5 mg/kg/day males and
females; 25 mg/kg/day males).
Among F1 pups, adverse effects at 100 mg/kg/day
included mortality (45% reduction in lactation index),
reduced body weights (65% reduction), and clinical signs
of delayed maturation. The failure to thrive and delayed
maturation of the pups were likely a result of the overt
systemic toxicity observed in the dams.
For mice, the no-observed-adverse-effect level (NOAEL)
for systemic repeated-dose toxicity was 25 mg/kg/day
(males) and 5 mg/kg/day (females), based on effects at
higher doses on mortality, clinical observations, body
weight, nutritional parameters, hematology (red and white
blood cell), clinical chemistry (liver-related), liver weights,
and histopathology (liver, teeth, reproductive tract, and
mammary gland). However, 6:2 FTOH was  not a selective
reproductive toxicant; any effects observed in offspring
occurred at dose levels that induced mortality and severe
toxicity in maternal animals. The NOAEL for reproductive
toxicity was 100 mg/kg/day; no effects on reproductive
outcome were observed at any dosage. The NOAEL for via-
bility and growth of the offspring was 25 mg/kg/day, based
on clinical signs of delayed maturation in pups, and reduc-
tions in pup survival and pup body weight during lactation
at 100 mg/kg/day.
4.2. Comparison of 6:2 FTOH toxicity in rats and mice
The results of the present study can be compared with
previous oral repeated-dose and reproduction studies in
CD rats with 6:2 FTOH [10,11] and reﬂects the toxicologi-
cal action and effects of 6:2 FTOH and its metabolites. The
severity and range of effects were generally greater in mice,
especially with regard to liver histopathology/function and
pup growth/viability. However, the overall NOAELs for
systemic toxicity, reproductive toxicity, and offspring via-
bility/growth were consistent between species (Table 7),
and 6:2 FTOH was not a selective reproductive toxicant in
either species.
Among P1 adults, the NOAEL for mortality and clinical
observations was 25 mg/kg/day in both species (Table 7).
However, the NOAEL for body weight loss during lactation
logy Rep140 P. Mukerji et al. / Toxico
was higher in rats than mice, and the magnitude of the
reduction at 100 mg/kg/day in mice exceeded that at
250 mg/kg/day in rats. The NOAEL for liver-related clin-
ical chemistry changes and associated microscopic liver
ﬁndings was 5 mg/kg/day in both species, although the
extent of hepatocellular injury was more pronounced in
mice. The magnitude of differences in clinical chemistry
parameters and the incidences of histopathologic liver
ﬁndings at 100 mg/kg/day in mice exceeded those at
250 mg/kg/day in rats. Correspondingly, white blood
cell alterations, which may  be associated with liver
inﬂammation due to hepatotoxicity, were observed at
100 mg/kg/day in mice, but were not reported in rats at
dose levels ≤250 mg/kg/day. Histopathologic evidence of
liver toxicity in the rat (single cell necrosis, biliary and oval
cell hyperplasia; hepatocyte vacuolation and peri-portal-
associated inﬂammation) was reported for only a few
animals (at ≥125 mg/kg/day in males and at ≥25 mg/kg/day
in females), and generally with minimal severity ([10];
DuPont, unpublished data). In contrast, liver toxicity in the
mouse (singe cell necrosis, cystic degeneration, oval cell
hyperplasia, oval cell-associated mononuclear inﬁltrate
and increased pigment) generally affected most animals
of both sexes at 100 mg/kg/day with minimal to mild
severity. Microscopic alterations in the incisor teeth were
observed in mice at 100 mg/kg/day whereas similar effects
were only reported at 250 mg/kg/day in rats. Microscopic
ﬁndings in reproductive organs (anestrus with associated
atrophic changes in the reproductive tract, and secretory
depletion in the mammary gland) occurring secondary to
decrements in body weight and nutritional parameters
were observed at 100 mg/kg/day in mice, but were not
reported in rats at dose levels ≤250 mg/kg/day. This
difference between the two species was consistent with
the greater difference in maternal body weight during
lactation, in mice compared to rats.
Among F1 pups, the NOAEL for mortality, clinical obser-
vations, and reduced body weights was 25 mg/kg/day in
both species. The magnitude of the reductions in lacta-
tion index and pup body weight at 100 mg/kg/day in mice
exceeded those observed in rats at 250 mg/kg/day, and is
likely a result of the species difference in maternal body
weight during lactation.
4.3. Comparison of 6:2 FTOH toxicity with other
ﬂuorotelomer alcohols and metabolites
Reproductive or systemic toxicity data are avail-
able for 8:2 FTOH; a ﬂuoroalkylethanol mixture,
F(CF2CF2)nCH2CH2OH (n = 3–6), including 30% (w/w)
6:2 FTOH; and PFHxA, a principal metabolite of 6:2 FTOH.
Toxicity data for these related chemicals are consistent
with data reported in both rats and mice for 6:2 FTOH
with regard to NOAELs, the types of effects, and the lack
of selective reproductive toxicity where applicable, i.e.
any effects on offspring viability and growth were only
observed at concentrations that were also associated
with systemic toxicity. Reproductive evaluations of the
ﬂuoroalkylethanol mixture and PFHxA in CD rats yielded
NOAELs of 20–50 mg/kg/day for systemic toxicity, greater
than 250 mg/kg/day (the highest dose evaluated) fororts 2 (2015) 130–143
reproductive toxicity, and 25–100 mg/kg/day for offspring
viability and growth ([47,11,16]). Subchronic evaluations
of 8:2 FTOH, the ﬂuoroalkylethanol mixture, and PFHxA in
CD rats yielded NOAELs ranging from 5 to 25 mg/kg/day,
based on effects at higher doses on body weight, clinical
observations, liver and/or kidney weights, histopatho-
logy (liver, kidney, thyroid, or teeth), red blood cell and
liver-related clinical chemistry parameters, and urinary or
plasma ﬂuoride [16,48,49].
8:2 FTOH has been evaluated for developmental and
hepatotoxicity in mice (CD-1 or ddY strains) in addition
to CD rats [20,22,49,50]. The studies in mice differed from
those in rats with respect to basic study design elements
(e.g., number of exposures, diet vs. gavage), and they did not
include a full evaluation of reproductive toxicity. Nonethe-
less, the differences between species for 8:2 FTOH toxicity
were similar to those presently reported for 6:2 FTOH, i.e.,
mice were generally more sensitive. Compared with rats,
8:2 FTOH exposure in mice resulted in hepatomegaly at
a lower dose level and developmental toxicity (neonatal
mortality and malformations in mice) with greater sever-
ity at a lower dose, although the effects on the fetus in both
species were only observed at levels that induced mater-
nal toxicity. The greater sensitivity of mice to hepatotoxic
effects has also been demonstrated in evaluations of perﬂu-
orobutyrate (PFBA) and perﬂuorooctanoate (PFOA), which
are metabolites of 6:2 FTOH and 8:2 FTOH, respectively.
Exposure to PFBA and PFOA resulted in the same or lower
NOAELs for hepatotoxicity in CD-1 mice compared with CD
rats, while the severity of hepatomegaly/hypertrophy and
the range of histopathologic effects (e.g. necrosis, increased
mitotic ﬁgures) was generally greater in mice [21,23,24,51].
These comparisons are generally limited to one strain of
each species (CD-1 mice and CD rats). The only other strain
included in the discussion above was the ddY strain of
mouse (Japan), which yielded results that were consistent
with those from the CD-1 strain [50].
Mechanisms underlying the greater sensitivity of mice
to hepatotoxic effects are not certain, but several proposed
explanations include possible species differences in peroxi-
some proliferation or in kinetic properties of metabolites.
Induction of peroxisome proliferation in rodents has been
conﬁrmed for 8:2 FTOH, PFBA, and PFOA [21,23,50], and
may  be presumed for 6:2 FTOH on the basis of histologic
effects described in Section 4.1 and beta oxidation mea-
surements in one of its principal metabolites, 5:3 acid [19].
To the extent that peroxisome proliferation may  be respon-
sible for any species differences in 6:2 FTOH toxicity, the
relevance for humans may  be limited, because humans
tend to be resistant to such effects, in contrast to rats and
mice [52]. Loveless et al. [21] noted that species differences
in PFOA toxicity may  be a result of additional mechanisms
as well, due to the inconsistent correlation between liver
weight increases and peroxisomal beta oxidation.
Henderson and Smith [22] suggested that the sensitivity
of mice to 8:2 FTOH may  be attributed to the role of termi-
nal metabolites such as perﬂuorooctanoic acid (PFOA). This
assertion formed a basis for proposed hazard classiﬁcations
for 8:2 FTOH which were not adopted by the ECHA Com-
mittee for Risk Assessment [53,54], due to a wider body
of kinetic, molecular, and epidemiologic data that did not
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upport this claim [55–62]. In addition, these classiﬁca-
ion arguments pertaining to longer chain ﬂuorochemicals
re not directly applicable to 6:2 FTOH, because of differ-
nces between short chain and longer chain metabolites.
FHxA (the analogous 6-carbon metabolite from 6:2 FTOH)
s eliminated from plasma 40 to 80 times faster than PFOA
n humans, rats, and mice [15,63,64], and the hepatotoxic-
ty is correspondingly lower in rats and mice as well [16,65].
Species differences in FTOH toxicity may  also be due
o possible kinetic differences in other metabolites such as
uorotelomer unsaturated aldehydes (FTUALs), which are
otential precursors to perﬂuorocarboxylic acids (PFCAs)
uch as PFOA and PFHxA. Evaluations of toxicokinetics, pro-
ein reactivity, cytotoxicity, and acute aquatic toxicity have
ndicated that FTUALs are generally more toxic than the
FCAs, and have been suggested to be responsible for rat
iver lesions following FTOH exposure ([66–70,72]). Further
valuation would be required to determine species differ-
nces in kinetics of FTUALs and other FTOH metabolites.
epeated-dose evaluations of intermediate metabolites
ay  not be possible because of their relative instability.
5:3 acid is another 6:2 FTOH metabolite that has been
valuated in mammalian and aquatic species for bioper-
istence, acute oral toxicity, and two week repeated-dose
oxicity. The extent of acute and systemic toxicity was con-
idered consistent with previously reported data for 6:2
TOH and indicated low potential for bioaccumulation in
ammals [19]. Although 5:3 acid has not been speciﬁ-
ally evaluated for reproductive or subchronic toxicity, the
esults of the present evaluation of 6:2 FTOH represents the
ombined effects of the parent chemical and all metabo-
ites, including the principal metabolites PFHxA and 5:3
cid, and intermediates such as FTUALs.
. Conclusions
CD-1 mice were generally more sensitive than CD rats
ith respect to systemic toxicity from oral administra-
ion of 6:2 FTOH, and this was likely responsible for the
ore severe effects observed in the offspring (i.e., pup
rowth and viability) at doses where systemic effects were
bserved. The liver was the primary target organ in both
pecies, evidenced by increased liver size, trophic and toxic
istopathologic effects, and elevations in clinical chemistry
arameters that were consistent with hepatotoxicity. Mor-
ality, clinical abnormalities, red blood cell changes, and
eductions in male body weights were consistent across
pecies, but the reduction in P1 female body weight dur-
ng lactation was markedly greater in mice than in rats.
orrespondingly, changes in the female reproductive tract
nd mammary gland secondary to body weight decrements
ere observed only in mice, and the magnitude of the
eductions in lactation index and pup body weight were
reater in mice than in rats. While the severity of the
ffects was generally greater in mice than rats, the over-
ll NOAELs were identical in both species, 5 mg/kg/day
or systemic toxicity and 25 mg/kg/day for offspring via-
ility/growth. 6:2 FTOH was not a selective reproductive
oxicant in either species; no effects on reproductive out-
ome occurred at any dose level, and any effects observed
n offspring occurred at dose levels that induced mortality
[orts 2 (2015) 130–143 141
and severe toxicity in maternal animals. The present evalu-
ation of 6:2 FTOH in CD-1 mice corroborates the benchmark
dose of 5 mg/kg/day previously reported for 6:2 FTOH in CD
rats. Together, these studies reﬂect the toxicological action
and effects of 6:2 FTOH and its metabolites in rats and mice.
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